Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 4 mg single dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,186 result(s) found for: 4 mg single dose. Displaying page 51 of 160.
    «« First « Previous 47  48  49  50  51  52  53  54  55  Next» Last»»
    EudraCT Number: 2017-001941-28 Sponsor Protocol Number: R092670PSY3015 Start Date*: 2018-02-28
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation.
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001832-36 Sponsor Protocol Number: 204959 Start Date*: 2017-05-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Stu...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000181-37 Sponsor Protocol Number: CVT-301-002 Start Date*: 2012-04-25
    Sponsor Name:Civitas Therapeutics, Inc.
    Full Title: A Randomized, Placebo-Controlled Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CVT-301 (Levodopa Inhalation Powder) in Patients with Parkinson’s Disease and Motor Response ...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005594-21 Sponsor Protocol Number: ADP-04511 Start Date*: 2016-08-18
    Sponsor Name:Adaptimmune LLC
    Full Title: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma
    Medical condition: Unresectable, metastatic or recurrent synovial sarcomas
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016525-34 Sponsor Protocol Number: 28431754DIA3006 Start Date*: 2010-04-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with...
    Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed) PT (Prematurely Ended) PL (Completed) SK (Completed) CZ (Completed) EE (Completed) SE (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002067-20 Sponsor Protocol Number: RA0077 Start Date*: 2012-06-13
    Sponsor Name:UCB Pharma SA
    Full Title: A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subject...
    Medical condition: Moderate to severe rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) PT (Completed) AT (Completed) IE (Completed) CZ (Completed) ES (Completed) BG (Completed) FR (Completed) IT (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000955-28 Sponsor Protocol Number: R668-AD-1539 Start Date*: 2018-05-23
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis
    Medical condition: Part B: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004481-16 Sponsor Protocol Number: VRA105345 Start Date*: 2005-12-19
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar too...
    Medical condition: Dental pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004276-49 Sponsor Protocol Number: CD-LAQ-201 Start Date*: 2008-09-16
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: Estudio de fase IIa, multicéntrico, randomizado, doble ciego, controlado con placebo, de cohortes secuenciales, de búsqueda de rango de dosis para evaluar la seguridad, tolerabilidad y el efecto cl...
    Medical condition: Enfermedad de Crohn activa de moderada a grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-005030-38 Sponsor Protocol Number: PAT-CR-302 Start Date*: 2019-08-10
    Sponsor Name:Vifor Pharma, Inc.
    Full Title: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone Syst...
    Medical condition: Management of hyperkalemia due to renin-angiotension-aldosterone system medications in patients treated for heart failure.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10005725 Blood potassium increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed) NL (Completed) ES (Ongoing) HU (Completed) DE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001361-12 Sponsor Protocol Number: FG001-CT-003 Start Date*: 2022-08-25
    Sponsor Name:FluoGuide A/S
    Full Title: An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) for localization of oral and oropharyngeal squamous cell carcinoma
    Medical condition: Oral and oropharyngeal squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041857 Squamous cell carcinoma of the oral cavity PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031112 Oropharyngeal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000872-18 Sponsor Protocol Number: WA18221 Start Date*: 2008-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A 12-week randomized, double blind, placebo-controlled, parallel group, 2-arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthritis...
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) NO (Ongoing) CZ (Completed) ES (Completed) DK (Completed) NL (Completed) GR (Completed) SK (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005068-29 Sponsor Protocol Number: C2006-01 Start Date*: Information not available in EudraCT
    Sponsor Name:A.P. Pharma, Inc.
    Full Title: A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi® for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea a...
    Medical condition: Chemotherapy Induced Nausea and Vomiting
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003022-22 Sponsor Protocol Number: SOLTI-1904 Start Date*: 2021-02-26
    Sponsor Name:SOLTI
    Full Title: EfficACy of Spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff
    Medical condition: Metastatic disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009377-10 Sponsor Protocol Number: NAL-OIC-01 Start Date*: 2009-05-27
    Sponsor Name:SLA Pharma (UK) Ltd
    Full Title: A Multicenter, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Efficacy Study of Naloxone SR capsules in Subjects with Constipation due to Opioids ta...
    Medical condition: Opioid Induced Constipation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021175 Iatrogenic constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004040-36 Sponsor Protocol Number: CE01-302 Start Date*: 2014-10-10
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Study to Evaluate the Efficacy and Safety of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea (SOLITAIRE-U).
    Medical condition: gonorrhoea
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-023414-31 Sponsor Protocol Number: MD-KPSY-01/10 Start Date*: 2012-03-05
    Sponsor Name:Medizinische Fakultät. Otto von Guericke Universität
    Full Title: Ketamine in treatment resistant major depression (TRD)
    Medical condition: Therapy resistant depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001921-19 Sponsor Protocol Number: BUSCAPART Start Date*: 2014-02-11
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Randomised, masked, placebo-controlled study to evaluate the effects of a single intravenous dose of hyoscine bromide on the duration and pain in the latent and active labor
    Medical condition: labor
    Disease: Version SOC Term Classification Code Term Level
    16.1 10036585 - Pregnancy, puerperium and perinatal conditions 10029767 Normal labour PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022084-36 Sponsor Protocol Number: rhLAMAN-02 Start Date*: 2010-10-05
    Sponsor Name:Zymenex A/S
    Full Title: A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis.
    Medical condition: Treatment of alpha-Mannosidosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001235-20 Sponsor Protocol Number: 14.0189 Start Date*: 2015-06-05
    Sponsor Name:St George's University of London
    Full Title: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease
    Medical condition: PARTICIPANTS WITH EVIDENCE OF CEREBRAL SMALL VESSEL DISEASE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 47  48  49  50  51  52  53  54  55  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 14:16:56 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA